Ascentage Pharma Group International

Equities

6855

KYG0519B1023

Biotechnology & Medical Research

Delayed Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
17.76 HKD -19.09% Intraday chart for Ascentage Pharma Group International -19.09% -34.95%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Ascentage Pharma Widens Loss by Nearly 5% in 2023 MT
Ascentage Pharma Group International Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Ascentage Pharma to Present Preclinical Results of Three Anti-Tumor Drugs at US Cancer Meet MT
Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting CI
Ascentage Pharma's Phase 3 Trial for Chronic Myeloid Leukemia Treatment Gets US FDA Nod; Shares Rise 3% MT
Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia CI
Ascentage Pharma Trustee Buys 100,000 Shares MT
Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia Management from the National Comprehensive Cancer Network CI
Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib CI
Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR CI
Ascentage Pharma Announces the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication CI
China Approves Ascentage Pharma's Chronic-Phase Chronic Myeloid Leukemia Treatment MT
China National Medical Products Administration Approves Olverembatinib for Treatment of Cml-Cp Patients CI
Ascentage Pharma Group Trustee Purchases 100,000 Shares Under Restricted Share Scheme MT
Ascentage Pharma Trustee Repurchases Shares MT
Ascentage Pharma Trustee Buys 50,000 Shares Under Restricted Share Scheme MT
Ascentage Pharma to Present Clinical Data on Hematological Drugs in US Meet MT
Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM CI
Ascentage Pharma Group International to Present Results from Multiple Clinical Studies of olverembatinib and APG-2575 at the 2023 American Society of Hematology(ASH) Annual Meeting, two of which have been Selected for Oral Reports CI
Ascentage Pharma Presents Lung Cancer Therapy Study at European Oncology Conference MT
Ascentage Pharma Releases Latest Data of Pelcitoclax (Apg-1252) Combined with Osimertinib Demonstrates Potential as A New Treatment Option for Tp53-And Egfr-Mutant Nsclc CI
Ascentage Pharma Announces First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia CI
Ascentage Pharma and AstraZeneca Investment Co., Ltd. Enter into Clinical Collaboration on the Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Combination with BTK Inhibitor Acalabrutinib in Treatment-Naïve Patients with First-Line CLL/SLL CI
Ascentage Pharma Announces Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment Naïve Patients with CLL/SLL Approved by the China CDE CI
Ascentage Pharma Group's H1 Loss Narrows MT
Chart Ascentage Pharma Group International
More charts
Ascentage Pharma Group International is an investment holding company principally engaged in developing novel small therapies for cancers, hepatitis B virus (HBV) and certain age-related diseases. The Company focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The Company's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The Company conducts businesses within the domestic market and to overseas markets, including the United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
16.4 CNY
Average target price
29.98 CNY
Spread / Average Target
+82.83%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Ascentage Pharma Group International - Hong Kong S.E.
  4. News Ascentage Pharma Group International
  5. Ascentage Pharma Group Gets Canadian Approval for Leukemia Treatment Phase 1B Study